Back to Search
Start Over
A nomogram for overall survival of second primary cancers following upper-tract urothelial carcinoma: a SEER population-based study.
- Source :
-
Translational cancer research [Transl Cancer Res] 2024 Aug 31; Vol. 13 (8), pp. 4131-4145. Date of Electronic Publication: 2024 Aug 12. - Publication Year :
- 2024
-
Abstract
- Background: With improving prognosis in upper-tract urothelial carcinoma (UTUC), an increasing number of second primary malignancies (SPMs) are being identified. However, there is limited research on SPMs following UTUC. This study aims to evaluate the risk of SPMs in UTUC patients and create a nomogram to predict their survival rates.<br />Methods: Utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database, we assessed the risk of SPMs among UTUC patients. Additionally, we developed and validated an overall survival (OS) nomogram for SPM patients post-UTUC diagnosis.<br />Results: The prevalence of SPMs among UTUC patients was 30.23%, with solid tumors being the most prevalent type of second malignancy, constituting 95.30% of all SPMs. The overall risk of SPMs was significantly elevated across all subgroups. Univariate and multivariate Cox regression analyses identified age, race, gender, UTUC SEER historic stage, surgery, SPM site, histologic type, grade, and SEER historic stage as independent prognostic factors for SPM OS. Subsequently, we developed a nomogram for predicting SPM OS. The C-index for the training and validation sets were 0.72 [95% confidence interval (CI): 0.70-0.74] and 0.71 (95% CI: 0.67-0.75), respectively. The area under the curve (AUC) demonstrated good performance of our model in predicting the 3-year (0.73 and 0.737) and 5-year (0.723 and 0.733) OS of SPMs in both sets.<br />Conclusions: This study represents the first comprehensive analysis of SPM incidence in UTUC patients and introduces a nomogram for predicting SPM prognosis.<br />Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-515/coif). The authors have no conflicts of interest to declare.<br /> (2024 Translational Cancer Research. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2219-6803
- Volume :
- 13
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Translational cancer research
- Publication Type :
- Academic Journal
- Accession number :
- 39262482
- Full Text :
- https://doi.org/10.21037/tcr-24-515